Latest research on Celecoxib

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form.

Celecoxib dosage

mice with inhibitors that block both COX1 and COX2 (Indomethacin) and COX2 alone (Celecoxib) abrogates mortality induced by the lethal dose of TsV. [source, 2016]
Similar results were observed in C57BL/6 mice injected with a lethal dose of TsV and treated with Indomethacin, Celecoxib or an EP2 antagonist, AH6809. [source, 2016]
The others drugs (SC-560, Celecoxib, and EP2 antagonist) or vehicles were administered 1 day and again 1 h before the i.p. injection of lethal dose of TsV (180 μg kg−1). [source, 2016]
The indicated doses of vehicle (acetone, 200 μL/site), Tat-SOD, Celecoxib, or PTIO were topically administered to the shaven back of a mouse for 2 h, and then it was further treated with TPA (10 nmol/200 μL/site) [33] or SNP (20 μmol/200 μL/site) for 4 h. [source, 2016]
The pigment tone was significantly and dose-dependently attenuated by Tat-SOD and Celecoxib, indicating that Tat-SOD effectively reduced SNP-induced COX-2 production as well as did Celecoxib in mouse skin. [source, 2016]
Compared to Celecoxib, Tat-SOD exhibited a similar potency in dose-dependently inhibiting COX-2 expression through a different mechanism. [source, 2016]
The MOVES trial found that a fixed-dose combination of chondroitin sulfate plus glucosamine has comparable efficacy to Celecoxib in reducing pain in patients with osteoarthritis of the knee with moderate-to-severe pain after 6 months of treatment. [source, 2016]
While the present results are in accordance with data from other studies for the combination,10 29 30 and for Celecoxib in painful knee osteoarthritis at the same dosage,10 12–14 22 direct comparisons are limited by differences in study designs and drug formulations. [source, 2016]
As shown in Figure 3A, Celecoxib dose-dependently reduced RFP expression as determined by fluorescence assay (left panel) and the intensity analysis of RFP (right panel). [source, 2015]
Figure 5A,B show that Celecoxib dose-dependently reduces the levels of RTA mRNA and protein expression at 72 h post-induction in BCBL-1 cells. [source, 2015]